Effects of High-Dose α-Lipoic Acid on Heart Rate Variability of Type 2 Diabetes Mellitus Patients with Cardiac Autonomic Neuropathy in Korea
| العنوان: | Effects of High-Dose α-Lipoic Acid on Heart Rate Variability of Type 2 Diabetes Mellitus Patients with Cardiac Autonomic Neuropathy in Korea |
|---|---|
| المؤلفون: | Bong Yun Cha, Jung Eun Lee, Yong Hoon Lee, Sol Jae Lee, Yu Chang Lee, Kyung Wan Min, Su Jin Jeong, Chong Hwa Kim |
| المصدر: | Diabetes & Metabolism Journal, Vol 41, Iss 4, Pp 275-283 (2017) Diabetes & Metabolism Journal |
| بيانات النشر: | Korean Diabetes Association, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | medicine.medical_specialty, Letter, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Clinical Diabetes & Therapeutics, 030204 cardiovascular system & hematology, Placebo, Gastroenterology, lcsh:Diseases of the endocrine glands. Clinical endocrinology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Thioctic acid, Internal medicine, Diabetes mellitus, Multicenter trial, medicine, Heart rate variability, Adverse effect, lcsh:RC648-665, business.industry, Diabetes, Type 2 Diabetes Mellitus, Cardiac autonomic neuropathy, medicine.disease, Lipoic acid, chemistry, Cardiology, Original Article, business |
| الوصف: | BACKGROUND Diabetic cardiac autonomic neuropathy (CAN) is one of the important complications of diabetes. It is characterized by reduced heart rate variability (HRV). METHODS In this randomized, double-blind, placebo-controlled, multicenter trial, 75 patients were randomly assigned to one of two groups. One group (n=41) received α-lipoic acid (ALA) at an oral dose of 600 mg/day for the first 12 weeks and then 1,200 mg/day for the next 12 weeks. The other group (n=34) received placebo treatment for 24 weeks. CAN was assessed by measuring HRVs in people with diabetes. RESULTS Most of the baseline measures for HRVs were similar between the ALA and placebo groups. Although there were no statistically significant HRV changes in the ALA group compared to the placebo group after 24 weeks of trial, we found a positive tendency in some of the HRV parameters of the ALA group. The standard deviations of normal-to-normal RR intervals in the standing position increased by 1.87 ms in the ALA group but decreased by -3.97 ms in the placebo group (P=0.06). The power spectrum of the low frequency (LF) band in the standing position increased by 15.77 ms² in the ALA group, whereas it declined by -15.04 ms² in the placebo group (P=0.08). The high frequency/LF ratio in the upright position increased by 0.35 in the ALA group, whereas it declined by -0.42 in the placebo group (P=0.06). There were no differences between the two groups regarding rates of adverse events. CONCLUSION Although a slight improvement tendency was seen in HRV in the ALA group, there were no statistically significant HRV changes in the ALA group compared to the placebo group after 24 weeks of trial. However, the high oral dose of ALA was well-tolerated. |
| اللغة: | English |
| تدمد: | 2233-6087 2233-6079 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::777d2b45b92a11ded5d1fc529c1008db https://e-dmj.org/Synapse/Data/PDFData/2004DMJ/dmj-41-275.pdf |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....777d2b45b92a11ded5d1fc529c1008db |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 22336087 22336079 |
|---|